Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 503945, 9 pages
http://dx.doi.org/10.1100/2012/503945
Clinical Study

Serum Bone Resorption Markers after Parathyroidectomy for Renal Hyperparathyroidism: Correlation Analyses for the Cross-Linked N-telopeptide of Collagen I and Tartrate-Resistant Acid Phosphatase

1Department of Medicine, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, No. 510, Zhongzheng Road, Xinzhuang District, New Taipei City 24205, Taiwan
2Department of Medicine, Show-Chwan Memorial Hospital and Department of Nursing, Meiho University, 542, Sec. 1 Chung-shan Road, Changhua 50008, Taiwan
3Division of Nephrology, Mackay Memorial Hospital and Department of Pharmacology, Taipei Medical University, No. 252, Wu-Hsing Street, Taipei City 11031, Taiwan
4Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Chenggong Road, Neihu District, Taipei City 11490, Taiwan

Received 11 May 2012; Accepted 5 June 2012

Academic Editors: K. D. Burns and K. Furuichi

Copyright © 2012 Kuo-Chin Hung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Floege, J. Kim, E. Ireland et al., “Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population,” Nephrology Dialysis Transplantation, vol. 26, no. 6, pp. 1948–1955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. L. Melamed, J. A. Eustace, L. C. Plantinga et al., “Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study,” Nephrology Dialysis Transplantation, vol. 23, no. 5, pp. 1650–1658, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Tentori, M. J. Blayney, J. M. Albert et al., “Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS),” American Journal of Kidney Diseases, vol. 52, no. 3, pp. 519–530, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. H. H. Malluche and M. C. Faugere, “Effects of 1,25(OH)2D3 administration on bone in patients with renal failure,” Kidney International, vol. 29, supplement 38, pp. S-48–S-53, 1990. View at Google Scholar · View at Scopus
  5. D. J. Sherrard, G. Hercz, Y. Pei et al., “The spectrum of bone disease in end-stage renal failure—an evolving disorder,” Kidney International, vol. 43, no. 2, pp. 436–442, 1993. View at Google Scholar · View at Scopus
  6. L. S. Stilgren, L. M. Hegedüs, H. Beck-Nielsen, and B. Abrahamsen, “Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism,” Calcified Tissue International, vol. 73, no. 3, pp. 210–216, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Yajima, M. Inaba, Y. Tominaga, Y. Nishizawa, K. Ikeda, and A. Ito, “Increased osteocyte death and mineralization inside bone after parathyroidectomy in patients with secondary hyperparathyroidism,” Journal of Bone and Mineral Research, vol. 25, no. 11, pp. 2374–2381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Parfitt, “A structural approach to renal bone disease,” Journal of Bone and Mineral Research, vol. 13, no. 8, pp. 1213–1220, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. S. C. Manolagas, “Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis,” Endocrine Reviews, vol. 21, no. 2, pp. 115–137, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Tanaka, T. Mine, H. Ogasa, T. Taguchi, and C. T. Liang, “Expression of RANKL/OPG during bone remodeling in vivo,” Biochemical and Biophysical Research Communications, vol. 411, no. 4, pp. 690–694, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Tanaka, A. Wakisaka, H. Ogasa, S. Kawai, and C. T. Liang, “Effect of IGF-I and PDGF administered in vivo on the expression of osteoblast-related genes in old rats,” The Journal of Endocrinology, vol. 174, no. 1, pp. 63–70, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. C. M. Zheng, P. Chu, C. C. Wu et al., “Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients,” The Tohoku Journal of Experimental Medicine, vol. 226, no. 1, pp. 19–27, 2012. View at Publisher · View at Google Scholar
  13. P. Chu, T. Y. Chao, Y. F. Lin, A. J. Janckila, and L. T. Yam, “Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis,” American Journal of Kidney Diseases, vol. 41, no. 5, pp. 1052–1059, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Iba, J. Takada, N. Hatakeyama, Y. Ozasa, T. Wada, and T. Yamashita, “Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment,” Journal of Orthopaedic Science, vol. 13, no. 5, pp. 438–441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Maeno, M. Inaba, S. Okuno, T. Yamakawa, E. Ishimura, and Y. Nishizawa, “Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients,” Clinical Chemistry, vol. 51, no. 12, pp. 2312–2317, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Epstein, I. R. Dissanayake, G. R. Goodman et al., “Effect of the interaction of parathyroid hormone and cyclosporine a on bone mineral metabolism in the rat,” Calcified Tissue International, vol. 68, no. 4, pp. 240–247, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Caplan, A. E. Hines, E. Williams et al., “An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis,” Osteoporosis International, vol. 22, no. 1, pp. 305–315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Yajima, Y. Ogawa, A. Ikehara, T. Tominaga, T. Inou, and O. Otsubo, “Development of low-turnover bone diseases after parathyroidectomy and autotransplantation,” International Journal of Urology, vol. 8, no. 8, pp. S76–S79, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Yajima, Y. Ogawa, H. E. Takahashi, Y. Tominaga, T. Inou, and O. Otsubo, “Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism,” American Journal of Kidney Diseases, vol. 42, no. 4, pp. 729–738, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Balsa, J. I. Botella-Carretero, R. Peromingo et al., “Chronic increase of bone turnover markers after biliopancreatic diversion is related to secondary hyperparathyroidism and weight loss. Relation with bone mineral density,” Obesity Surgery, vol. 20, no. 4, pp. 468–473, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. P. D. Delmas, R. Eastell, P. Garnero, M. J. Siebel, and J. Stepan, “The use of biochemical markers of bone turnover in osteoporosis. Committee of scientific advisors of the international osteoporosis foundation,” Osteoporosis International, vol. 11, supplement 6, pp. S2–S17, 2000. View at Google Scholar · View at Scopus
  22. H. N. Rosen, A. C. Moses, J. Garber, D. S. Ross, S. L. Lee, and S. L. Greenspan, “Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates,” Calcified Tissue International, vol. 63, no. 5, pp. 363–368, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Urena, A. Ferreira, V. T. Kung et al., “Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients,” Journal of Bone and Mineral Research, vol. 10, no. 6, pp. 932–939, 1995. View at Google Scholar · View at Scopus
  24. S. Mazzaferro, M. Pasquali, P. Ballanti et al., “Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy,” Nephrology Dialysis Transplantation, vol. 10, no. 1, pp. 52–58, 1995. View at Google Scholar · View at Scopus
  25. S. Palacios, J. L. Neyro, J. Ferrer et al., “Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate,” Menopause, vol. 19, no. 1, pp. 67–74, 2012. View at Google Scholar
  26. M. McClung, R. Recker, P. Miller et al., “Intravenous zoledronic acid 5mg in the treatment of postmenopausal women with low bone density previously treated with alendronate,” Bone, vol. 41, no. 1, pp. 122–128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. C. de la Piedra, N. A. Castro-Errecaborde, M. L. Traba et al., “Bone remodeling markers in the detection of bone metastases in prostate cancer,” Clinica Chimica Acta, vol. 331, no. 1-2, pp. 45–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Tamada, T. Sone, T. Tomomitsu, Y. Jo, H. Tanaka, and M. Fukunaga, “Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy,” Journal of Bone and Mineral Metabolism, vol. 19, no. 1, pp. 45–51, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Katagiri, M. Fukunaga, T. Ohtawa, and T. Harada, “Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen,” World Journal of Surgery, vol. 20, no. 7, pp. 753–757, 1996. View at Google Scholar · View at Scopus
  30. P. Magnusson, C. A. Sharp, M. Magnusson, J. Risteli, M. W. J. Davie, and L. Larsson, “Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms,” Kidney International, vol. 60, no. 1, pp. 257–265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Ureña, O. Bernard-Poenaru, M. Cohen-Solal, and M. C. de Vernejoul, “Plasma bone-specific alkaline phosphatase changes in hemodialysis patients treated by alfacalcidol,” Clinical Nephrology, vol. 57, no. 4, pp. 261–273, 2002. View at Google Scholar · View at Scopus
  32. L. T. Yam, “Clinical significance of the human acid phosphatases: a review,” The American Journal of Medicine, vol. 56, no. 5, pp. 604–616, 1974. View at Google Scholar · View at Scopus
  33. J. J. Stepan, E. Silinkova Malkova, T. Havranek et al., “Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism,” Clinica Chimica Acta, vol. 133, no. 2, pp. 189–200, 1983. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Irie, N. Hayashida, T. Shinkawa et al., “Suitability of tartrate-resistant acid phosphatase type 5b as a screening marker for bone mineral density in community-dwelling elderly individuals,” The Tohoku Journal of Experimental Medicine, vol. 224, no. 2, pp. 105–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. C. Lu, W. Y. Ma, J. C. Yu, C. C. Wu, and P. Chu, “Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism,” Clinical Endocrinology, vol. 76, no. 5, pp. 634–642, 2012. View at Google Scholar
  36. M. Schoppet and C. M. Shanahan, “Role for alkaline phosphatase as an inducer of vascular calcification in renal failure?” Kidney International, vol. 73, no. 9, pp. 989–991, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Shantouf, C. P. Kovesdy, Y. Kim et al., “Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 6, pp. 1106–1114, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. T. C. Franca, L. Griz, J. Pinho et al., “Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica,” Revista Brasileira de Reumatologia, vol. 51, no. 2, pp. 131–137, 2011. View at Google Scholar · View at Scopus
  39. D. Harmey, L. Hessle, S. Narisawa, K. A. Johnson, R. Terkeltaub, and J. L. Millán, “Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders,” The American Journal of Pathology, vol. 164, no. 4, pp. 1199–1209, 2004. View at Google Scholar · View at Scopus
  40. W. C. O'Neill, “Pyrophosphate, alkaline phosphatase, and vascular calcification,” Circulation Research, vol. 99, no. 2, p. e2, 2006. View at Publisher · View at Google Scholar · View at Scopus